Press release
HER2 Positive Gastric Cancer Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential
Explore our latest breakthroughs in HER2 Positive Gastric Cancer Research. Learn more about our innovative pipeline today! @ HER2 Positive Gastric Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the HER2 Positive Gastric Cancer Pipeline Report
* On 05 September 2025, Jazz Pharmaceuticals announced a study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).
* On 05 September 2025, Seagen announced a clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer.
* On 02 September 2025, Astellas Pharma Global Development Inc . announced a study will give more information about how well zolbetuximab works when given with an immunotherapy medicine called pembrolizumab and chemotherapy. In this study, adults with stomach cancer or GEJ cancer will either be given zolbetuximab with pembrolizumab and chemotherapy or a placebo with pembrolizumab and chemotherapy. A placebo looks like zolbetuximab but doesn't have any medicine in it.
* DelveInsight's HER2 Positive Gastric Cancer pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for HER2 Positive Gastric Cancer treatment.
* The leading HER2 Positive Gastric Cancer Companies such as Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
* Promising HER2 Positive Gastric Cancer Therapies such as YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.
Stay informed about the cutting-edge advancements in HER2 Positive Gastric Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ HER2 Positive Gastric Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
HER2 Positive Gastric Cancer Emerging Drugs
* SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
SHR-A1811 is a novel anti-HER2 antibody-drug conjugate (ADC) that features an optimized molecular design to enhance plasma stability and bystander effect. Hengrui Pharma is currently conducting more than 10 clinical studies of SHR-A1811 from phase 1 to phase 3 to evaluate its safety and efficacy as single agent or combination therapy in a wide variety of cancer indications. Currently, the drug is in Phase III stage of its development for the treatment of HER2-positive Gastric Cancer.
* Cinrebafusp alfa: Pieris Pharmaceuticals
Cinrebafusp alfa (PRS-343) is a 4-1BB/HER2 fusion protein comprising 4-1BB-targeting Anticalin proteins and a HER2-targeting antibody. The drug candidate is currently in phase 2 development for the treatment of HER2-expressing solid tumors. In phase 1 studies, cinrebafusp alfa has shown an acceptable safety profile at all doses tested with no dose-limiting toxicities. The bispecific also showed a dose response and a 4-1BB-driven mechanism of action based on clinical benefit and pharmacodynamic correlates. Currently, the drug is in Phase II stage of its development for the treatment of HER2-positive Gastric Cancer.
* BI-1607: BioInvent International
BI-1607 is an FcRIIB-blocking antibody that differs from BI-1206 (BioInvent's clinical-stage FcRIIB antibody) in that it has been engineered for reduced Fc-binding to FcRs. Preclinical proof-of-concept data indicate that combined treatment with BI-1607 may both enhance efficacy of current anti-HER2 regimens and increase response rates in patients no longer responding to anti-HER2-directed therapies such as trastuzumab. Currently, the drug is in Phase I/II stage of its development for the treatment of HER2-positive Gastric Cancer.
The HER2 Positive Gastric Cancer pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of HER2 Positive Gastric Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Positive Gastric Cancer Treatment.
* HER2 Positive Gastric Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* HER2 Positive Gastric Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2 Positive Gastric Cancer market.
Learn more about HER2 Positive Gastric Cancer Drugs opportunities in our groundbreaking HER2 Positive Gastric Cancer Research and development projects @ HER2 Positive Gastric Cancer Unmet Needs [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
HER2 Positive Gastric Cancer Companies
Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
HER2 Positive Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
HER2 Positive Gastric Cancer Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in HER2 Positive Gastric Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ HER2 Positive Gastric Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
HER2 Positive Gastric Cancer Companies and Therapies
* BDC-1001: Bolt Therapeutics Inc.
* KN026: Shanghai JMT-Bio Inc.
* YH32367: Yuhan Corporation
* Margetuximab: MacroGenics
* Zanidatamab: Jazz Pharmaceuticals
Scope of the HER2 Positive Gastric Cancer Pipeline Report
* Coverage- Global
* HER2 Positive Gastric Cancer Companies- Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
* HER2 Positive Gastric Cancer Therapies- YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.
* HER2 Positive Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* HER2 Positive Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of HER2 Positive Gastric Cancer Pipeline on our website @ HER2 Positive Gastric Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* HER2-positive Gastric Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* HER2-positive Gastric Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Cinrebafusp alfa: Pieris Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* BI-1607: BioInvent International
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* HER2-positive Gastric Cancer Key Companies
* HER2-positive Gastric Cancer Key Products
* HER2-positive Gastric Cancer- Unmet Needs
* HER2-positive Gastric Cancer- Market Drivers and Barriers
* HER2-positive Gastric Cancer- Future Perspectives and Conclusion
* HER2-positive Gastric Cancer Analyst Views
* HER2-positive Gastric Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=her2-positive-gastric-cancer-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2 Positive Gastric Cancer Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential here
News-ID: 4176505 • Views: …
More Releases from ABNewswire
Voice Prosthesis Devices Market to Reach USD 599.38 Million by 2032, Driven by R …
Key voice prosthesis devices companies include Atos Medical (Coloplast A/S), InHealth Technologies, Andreas Fahl Medical Technology Sales GmbH, Hood Laboratories, Smiths Medical, Passy-Muir, Inc., Seda S.p.A., Innaumation Medical Devices, Shenda, Laronix Inc., and Respeecher.
DelveInsight's latest report, "Voice Prosthesis Devices Market Size, Share, Trends, Growth Drivers, Challenges, and Forecast 2025-2032," provides an in-depth analysis of the rapidly growing Voice Prosthesis Devices Market. The study highlights current market size, pipeline innovations, key…
Diabetic Macular Edema Market Outlook 2034 - Clinical Trials, Market Size, Medic …
FDA Expands Approval of Roche's Eye Implant Susvimo to Diabetic Macular Edema - A Landmark Development in Retinal Disease Treatment
Diabetic Macular Edema Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight
FDA Expands Approval of Roche's Eye Implant Susvimo to Diabetic Macular Edema - A Landmark Development in Retinal Disease Treatment
Diabetic macular edema Market Summary
Diabetic macular edema (DME), a complication of diabetic retinopathy (DR), is the leading…
Triple Negative Breast Cancer Clinical Trials Assessment 2025: Competitive Lands …
The prevalence of triple-negative breast cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of triple-negative breast cancer and the growing research and development activities to develop novel therapies to treat TNBC to drive the market. The companies developing the potential therapies in the last stage of development include Jiangsu HengRui Medicine, G1 Therapeutics, Infinity Pharmaceuticals, etc.
(Albany, USA) DelveInsight's…
Global Ablation Devices Market Projected to Surpass USD 15.3 Billion by 2032, Fu …
The global ablation devices market is witnessing robust expansion, projected to grow from USD 8,090.31 million in 2024 to USD 15,347.69 million by 2032, at a strong CAGR of 8.38% (2025-2032), according to the latest analysis by DelveInsight Business Research LLP.
Ablation devices, used to precisely destroy diseased tissues in oncology, cardiology, and pain management, are emerging as a cornerstone of modern minimally invasive medicine. Driven by rising cases of chronic…
More Releases for HER2
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…
